China chip stocks rally on self-reliance bets, Nvidia scrutiny
Quoin Pharmaceuticals Ltd. (QNRX), a specialty pharmaceutical company currently valued at $4.36 million, announced today significant clinical progress in its ongoing Pediatric Netherton Syndrome study. The treatment, QRX003, has shown to maintain nearly complete skin healing after six weeks of daily application. This development is particularly noteworthy as the patient has not required additional medications, such as antibiotics or antihistamines, which were previously necessary. According to InvestingPro data, while the company maintains a healthy cash position relative to debt, it faces near-term profitability challenges.
With the treatment, the young patient’s severe itching has been almost entirely alleviated, allowing for the first time in her life, uninterrupted sleep without sedatives. There have been no adverse events reported with the use of QRX003 over the six-week period. The company is preparing to extend this treatment to a second pediatric patient in the coming weeks.
This news is based on a press release statement and reflects Quoin’s commitment to addressing the challenges of rare and orphan diseases. It is important to note that the information provided is forward-looking and actual results may vary. Quoin’s efforts continue to be monitored by the medical community and investors as they progress with their clinical studies.
In other recent news, Quoin Pharmaceuticals Ltd. has reported significant developments in its efforts to treat Netherton Syndrome (NS). The company announced promising results from a clinical trial for its topical treatment, QRX003, which showed dramatic improvement in a pediatric patient’s skin condition without adverse events. Quoin Pharmaceuticals has also filed a U.S. patent application for QRX003, aiming to secure protection until 2045, covering not only NS but also other rare skin conditions. In its Q4 2023 earnings call, Quoin revealed a reduction in net loss to $870 million from $940 million in 2022, supported by a cash reserve of $1.07 billion and funds raised through a public offering. The company is actively expanding its clinical trials internationally and has launched the "NETHERTON NOW" campaign to raise awareness about NS. Quoin Pharmaceuticals remains the only company conducting multiple clinical trials for NS under an open IND, with plans to include pediatric subjects in future studies. Analyst firms, such as Maxim Group and Alliance Global Partners (NYSE:GLP), have shown interest in Quoin’s strategic direction, particularly its focus on mergers and acquisitions in the rare disease sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.